CD-56 Immunohistochemistry Test at Lahore PCR Lab

CD-56 Immunohistochemistry at Lahore PCR Lab

CD-56 Immunohistochemistry (IHC) is a highly specialized pathology investigation performed to detect the expression of Cluster of Differentiation 56 (CD56), also widely recognized as the Neural Cell Adhesion Molecule (NCAM). This cell-surface glycoprotein plays an instrumental role in cell-to-cell adhesion, neurite outgrowth, synaptic plasticity, and intercellular signaling. In clinical medicine and advanced histopathology, CD56 serves as a critical diagnostic biomarker with dual utility. It is primarily utilized in reproductive immunology to evaluate uterine natural killer (uNK) cells in patients experiencing unexplained fertility challenges, and in oncological pathology to identify neuroendocrine differentiation, specific hematologic malignancies, and soft tissue sarcomas. At Lahore PCR Lab, located in Lahore, Pakistan, this advanced diagnostic test is conducted using state-of-the-art automated staining platforms, ensuring unparalleled precision, reproducibility, and clinical reliability.

The diagnostic value of CD-56 Immunohistochemistry lies in its high sensitivity for identifying cells of neuroectodermal and neuroendocrine origin, as well as natural killer (NK) cells and a subset of T-lymphocytes. When tissue specimens are submitted to Lahore PCR Lab, our consultant pathologists utilize this antibody panel to differentiate complex neoplasms that may appear morphologically identical under routine Hematoxylin and Eosin (H&E) staining. For instance, small round blue cell tumors, poorly differentiated carcinomas, and various spindle cell lesions require IHC validation for an accurate diagnosis. Furthermore, in the realm of reproductive medicine, quantifying CD56+ uterine natural killer cells within an endometrial biopsy provides vital insights into the immunological microenvironment of the endometrium, helping clinicians tailor immunomodulatory therapies for patients undergoing assisted reproductive techniques (ART) such as In Vitro Fertilization (IVF).

Clinical Procedure: What to Expect

Patient Preparation

Because CD-56 Immunohistochemistry is performed on tissue specimens rather than directly on the patient, the preparation guidelines focus on the clinical procedure used to obtain the biopsy. Patients must adhere to the following instructions depending on the type of specimen collection:

• Endometrial Biopsy: If the test is ordered for reproductive immunology, the biopsy is typically scheduled during the mid-luteal phase of the menstrual cycle (usually days 19 to 24 of a standard 28-day cycle, or 7 to 9 days post-ovulation). Patients should consult their gynecologist regarding temporary discontinuation of blood thinners or hormonal supplements prior to the procedure.
• Tumor or Tissue Biopsy: For oncological investigations, the biopsy (incisional, excisional, core needle, or endoscopic) is scheduled by the primary surgeon or oncologist. Fasting and medication adjustments depend entirely on the type of anesthesia utilized for the surgical procedure.
• Specimen Submission: If the biopsy was performed at an external facility, the patient or healthcare provider must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block along with the corresponding H&E stained slides and detailed clinical history to Lahore PCR Lab.
• Clinical Documentation: It is essential to provide complete clinical details, including previous histopathology reports, radiological findings, menstrual cycle details (for endometrial samples), and suspected clinical diagnoses, to facilitate accurate pathological correlation.

During the Procedure

The laboratory phase of CD-56 Immunohistochemistry at Lahore PCR Lab involves a series of highly controlled, automated steps executed by trained histotechnologists and supervised by consultant pathologists:

• Tissue Sectioning: The paraffin-embedded tissue block is sectioned using a high-precision microtome to obtain ultra-thin slices, measuring approximately 3 to 4 microns in thickness. These sections are carefully mounted on positively charged glass slides to prevent tissue detachment during subsequent processing.
• Deparaffinization and Rehydration: The mounted tissue sections are heated and treated with graded concentrations of xylene and alcohol to remove the paraffin wax and rehydrate the tissue, preparing it for aqueous antibody solutions.
• Antigen Retrieval: To expose the CD56 epitopes that may have been masked during formalin fixation, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions (typically citrate or EDTA buffers) under controlled temperature and pressure.
• Antibody Incubation: The tissue sections are incubated with a highly specific, primary monoclonal anti-CD56 antibody. This antibody binds selectively to the CD56 (NCAM) glycoproteins present on the cell membranes of target cells.
• Detection and Visualization: A secondary detection system, usually conjugated with Horseradish Peroxidase (HRP) or Alkaline Phosphatase, is applied, followed by a chromogenic substrate such as Diaminobenzidine (DAB). This reaction produces a visible, insoluble brown precipitate at the site of antigen-antibody binding.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, cleared, and permanently mounted with a coverslip for microscopic examination.
• Pathological Analysis: A Consultant Pathologist examines the stained slides under a high-resolution light microscope, assessing the intensity, distribution, and percentage of CD56 cellular staining to formulate a definitive diagnostic report.

When is a CD-56 Immunohistochemistry Performed?

Evaluation of Recurrent Pregnancy Loss (RPL)

Uterine natural killer (uNK) cells are the most abundant leukocyte population in the endometrium during the secretory phase of the menstrual cycle and early pregnancy. They play a pivotal role in regulating trophoblast invasion and facilitating the remodeling of maternal spiral arteries, which is essential for establishing adequate placental perfusion. Physicians request CD-56 IHC on endometrial biopsies to quantify these cells in patients suffering from recurrent pregnancy loss (two or more consecutive miscarriages). An abnormal density or distribution of CD56+ cells suggests local immunological dysregulation, which can compromise placental development and lead to early pregnancy loss.

Assessment of Repeated Implantation Failure (RIF)

Repeated Implantation Failure (RIF) is defined as the failure to achieve a clinical pregnancy after multiple high-quality embryo transfers during IVF cycles. CD-56 Immunohistochemistry is performed to evaluate endometrial receptivity and rule out subclinical uterine inflammation or abnormal immune activation. By determining the precise concentration of CD56+ uNK cells in the endometrial stroma during the implantation window, reproductive endocrinologists can decide whether to implement immunomodulatory interventions, such as intralipid infusions, corticosteroids, or uterine scratching, to improve subsequent embryo transfer outcomes.

Diagnosis of Neuroendocrine Tumors (NETs)

Neuroendocrine tumors arise from cells of the endocrine and nervous systems and can occur throughout the body, most commonly in the lungs, gastrointestinal tract, and pancreas. Because CD56 is highly expressed in neuroendocrine tissues, pathologists routinely include CD-56 IHC in diagnostic antibody panels. When a patient presents with symptoms of a neuroendocrine tumor—such as flushing, chronic diarrhea, wheezing, or unexplained abdominal masses—and imaging reveals a lesion, a biopsy is performed. CD-56 positivity, alongside other markers like Synaptophysin and Chromogranin A, confirms the neuroendocrine lineage of the tumor, helping to differentiate it from conventional adenocarcinomas.

Characterization of Hematologic Malignancies

In hematopathology, CD-56 Immunohistochemistry is an indispensable tool for diagnosing and subtyping specific lymphoid and myeloid neoplasms. It is highly expressed in Extranodal NK/T-cell Lymphoma (nasal type), a highly aggressive malignancy that often presents with necrotic lesions in the nasal cavity, paranasal sinuses, or palate. Additionally, while normal plasma cells are CD56-negative, aberrant CD56 expression is observed in a significant majority of Multiple Myeloma cases. Pathologists utilize CD-56 IHC on bone marrow trephine biopsies to distinguish neoplastic plasma cells from reactive plasma cells, aiding in the definitive diagnosis and prognostic stratification of plasma cell dyscrasias.

Differential Diagnosis of Small Round Blue Cell Tumors

Small round blue cell tumors represent a heterogeneous group of malignant neoplasms characterized by monotonous sheets of small, round cells with high nuclear-to-cytoplasmic ratios. This group includes neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma, and small cell osteosarcoma, which are particularly common in pediatric and young adult populations. Because these tumors look remarkably similar under standard light microscopy, CD-56 IHC is employed as a key marker. Strong, diffuse CD56 expression points toward neuroblastoma or primitive neuroectodermal tumors (PNET), allowing pathologists to narrow down the differential diagnosis and guide oncologists toward appropriate, tumor-specific therapeutic protocols.

What Does a CD-56 Immunohistochemistry Detect?

CD-56 Immunohistochemistry is designed to detect and localize the Neural Cell Adhesion Molecule (NCAM) on the cell membranes and cytoplasm of specific cell types. The diagnostic evaluation at Lahore PCR Lab identifies several critical pathological and physiological findings, including:

• Physiological Endometrial uNK Cells: Identification of normal, scattered CD56+ uterine natural killer cells within the endometrial stroma during the secretory phase.
• Endometrial Hyper-activation: An abnormally high density of CD56+ cells (often exceeding 10% to 15% of stromal cells), indicating potential immune-mediated implantation barriers.
• Endometrial Hypo-activation: A marked depletion of CD56+ cells, which may suggest inadequate vascular remodeling and poor endometrial receptivity.
• Neuroendocrine Differentiation: Diffuse, strong membranous CD56 positivity in neoplastic cells, confirming a neuroendocrine tumor (NET) of the lung, pancreas, or gastrointestinal tract.
• Small Cell Lung Carcinoma (SCLC): Intense, diffuse CD56 expression in poorly differentiated pulmonary neoplasms, confirming SCLC when correlated with morphology.
• Atypical and Typical Carcinoids: Moderate to strong CD56 staining in well-differentiated neuroendocrine tumors of the bronchus or gastrointestinal tract.
• Extranodal NK/T-cell Lymphoma: Diffuse CD56 positivity in atypical, angioinvasive lymphoid infiltrates, confirming this specific lymphoma subtype.
• Aberrant Multiple Myeloma Phenotype: Strong CD56 expression on clonal plasma cells within bone marrow biopsies, distinguishing them from normal, CD56-negative plasma cells.
• Neuroblastoma: Intense, diffuse membranous and neuritic CD56 staining in pediatric small round blue cell tumors.
• Pheochromocytoma: Strong CD56 expression in tumors of the adrenal medulla.
• Thyroid Medullary Carcinoma: Positive CD56 staining in calcitonin-producing neuroendocrine cells of the thyroid.
• Merkel Cell Carcinoma: Diffuse CD56 positivity in aggressive primary cutaneous neuroendocrine carcinomas.
• Synovial Sarcoma: Variable CD56 expression in spindle cell and biphasic soft tissue sarcomas.
• Glioblastoma and Astrocytoma: Strong CD56 staining reflecting the neuroectodermal origin of primary central nervous system glial tumors.
• Schwannoma and Neurofibroma: Positive CD56 expression in benign peripheral nerve sheath tumors.
• Ewing Sarcoma: Variable or weak CD56 positivity, helping differentiate it from other small round cell tumors when combined with CD99.
• Wilms’ Tumor: CD56 expression in the blastemal and epithelial components of nephroblastoma.
• Retinoblastoma: Strong CD56 positivity in intraocular neuroectodermal malignancies of childhood.
• Medulloblastoma: Diffuse CD56 expression in embryonal tumors of the central nervous system.
• Anaplastic Large Cell Lymphoma (ALCL): Rare CD56 expression, which when present, correlates with an aggressive clinical course.
• Absence of CD56 in Adenocarcinomas: Negative CD56 staining in standard epithelial malignancies, helping rule out neuroendocrine differentiation.
• Absence of CD56 in Squamous Cell Carcinomas: Negative staining in squamous cancers, aiding in the differential diagnosis of poorly differentiated lung tumors.
• Physiological Skeletal Muscle Staining: Background CD56 expression in regenerating or denervated skeletal muscle fibers.
• Physiological Peripheral Nerve Staining: Normal CD56 expression in peripheral nerves included in the biopsy tissue, serving as an internal positive control.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic results are crucial for managing complex oncological cases and planning time-sensitive fertility treatments. Immunohistochemistry is a meticulous, multi-step process that requires careful tissue preparation, overnight processing, automated staining, and detailed microscopic evaluation. Consequently, the turnaround time for a CD-56 Immunohistochemistry report is typically 3 to 5 working days from the time the specimen is received at our main laboratory in Lahore.

Once the slide is prepared, it is reviewed by a Consultant Pathologist who correlates the IHC findings with the clinical history and routine H&E slides. To ensure maximum convenience for patients and referring physicians across Pakistan, Lahore PCR Lab provides multiple avenues for report access. Patients can securely download their digitally signed pathology reports via our official online portal or receive them directly on their registered mobile number via WhatsApp. Physical copies of the reports can also be collected from our main diagnostic center or designated collection points throughout Lahore.

CD-56 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Endometrial Stroma (uNK Cells)	Physiological presence of CD56+ cells (typically 1% to 5% of stromal cells during secretory phase)	Marked elevation (>10%) associated with immune-related implantation failure, or severe depletion indicating poor vascular remodeling.
Bronchial / Pulmonary Epithelium	CD56 negative in normal bronchial epithelial cells	Strong, diffuse membranous CD56 positivity indicating Small Cell Lung Carcinoma (SCLC) or bronchial carcinoid.
Bone Marrow Plasma Cells	CD56 negative in normal, reactive plasma cells	Aberrant CD56 expression in clonal plasma cells, highly suggestive of Multiple Myeloma or monoclonal gammopathy.
Gastrointestinal Mucosa	CD56 negative in normal epithelial cells; positive only in normal ganglion cells of the myenteric plexus	Diffuse, strong CD56 positivity in epithelial-derived tumor cells, confirming a Gastrointestinal Neuroendocrine Tumor (GI-NET).
Lymph Node / Extranodal Tissue	CD56 negative in normal follicular and paracortical lymphoid zones	Diffuse, dense CD56 positivity in atypical, necrotic lymphoid infiltrates, diagnostic of Extranodal NK/T-cell Lymphoma.
Skin Biopsy (Dermal Lesions)	CD56 negative in normal epidermis and dermis	Diffuse CD56 positivity in dermal neoplastic cells, indicating Merkel Cell Carcinoma or cutaneous NK/T-cell lymphoma.
Adrenal Gland Tissue	Normal cortical cells are CD56 negative; normal medullary cells show physiological positivity	Strong, diffuse CD56 positivity in an adrenal mass, confirming Pheochromocytoma or Neuroblastoma.
Soft Tissue Biopsy	CD56 negative in normal fibrous, adipose, and connective tissues	CD56 positivity in spindle or round cell neoplasms, helping identify Synovial Sarcoma or Rhabdomyosarcoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-56 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified Consultant Pathologists with specialized training in histopathology, oncopathology, and molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate service throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to stringent internal and external quality control protocols, ensuring international standards of diagnostic accuracy.
• Professional Reporting: Our reports are comprehensive, detailed, and structured to provide clear, actionable insights for referring clinicians and oncologists.
• Modern Diagnostic Approach: We utilize state-of-the-art automated immunohistochemistry staining platforms that minimize human error and optimize antibody-antigen reactions.
• Comfortable Environment: Our diagnostic facilities in Lahore are designed to offer a clean, professional, and welcoming environment for all patients.
• Convenient Location: Strategically located in Lahore, our main lab and collection centers are easily accessible, offering seamless sample drop-off and report collection.
• Commitment to Accurate Diagnosis: We integrate clinical history, radiological findings, and advanced pathology panels to deliver precise diagnoses that guide effective treatment planning.